Back

MicroRNA-29a enhances and preserves stem-like CD8 T cell differentiation by regulating master epigenetic circuits of exhaustion.

Leng, X.; Buchness, L. A.; Rafie, C. I.; Vlantis, P. I.; Ristin, S.; Gallardo, M. A.; Auwardt, S. L.; Khatwani, N. K.; Tan, Y.-D.; Ban, Y.; Sologon, C. M.; Currall, B. B.; Williams, S. L.; Van der Jeught, K.; Datta, J. L.; Villarino, A. V.; Telonis, A. G.; Stelekati, E.

2026-05-28 immunology
10.64898/2026.05.25.727439 bioRxiv
Show abstract

CD8 T cells mediate protective immune responses. However, persisting antigens such as chronic viruses or tumors redirect CD8 T cell differentiation to a sub-optimal, epigenetically defined state called exhaustion. Exhausted T cells (TEX) lose their ability to persist long-term and to initiate functional memory responses. Checkpoint inhibitor blockade temporarily restores effector functions, but immune reinvigoration is not long-lasting, due to the epigenetic stability of TEX. Therefore, epigenetic reprogramming of TEX leading to durable T cell responses is essential to improve disease control. Here, we demonstrate that a single microRNA (miR), miR-29a, epigenetically re-directs TEX differentiation and preserves TEX into a stem-like state, leading to long-term persisting progenitor TEX. MiR-29a rewires epigenetic maintenance programs, including downregulation of key exhaustion-associated regulators (Dnmt1, Dnmt3a, and Dnmt3b), alongside increased expression of progenitor- and stemness-associated genes such as Tcf7 and Il7r. These reprogrammed CD8 T cells are more sensitive to PD-L1 checkpoint blockade. Ectopic expression of miR-29a combined with aPD-L1 treatments enhances effector responses, while preserving T cell stemness. Together, our findings suggest that miR-29a can be leveraged to overcome current barriers to immune checkpoint blockade. HighlightsO_LIMiR-29a rewires key exhaustion-associated epigenetic maintenance programs, while enhancing stemness-associated transcriptional circuits. C_LIO_LIMiR-29a drives extensive remodeling of accessible chromatin in TEX. C_LIO_LIMiR-29a preserves newly generated progenitor TEX in a durable, epigenetically defined stem-like state with increased effector function. C_LIO_LIMiR-29a synergizes with aPD-L1; while miR-29a preserves progenitor TEX state, addition of aPD-L1 enhances the cytotoxic potential of these progenitor TEX cells. C_LI

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Immunity
58 papers in training set
Top 0.2%
14.7%
2
Cell Reports
1338 papers in training set
Top 1%
12.7%
3
Nature Immunology
71 papers in training set
Top 0.1%
10.1%
4
Science Immunology
81 papers in training set
Top 0.4%
4.3%
5
eLife
5422 papers in training set
Top 22%
4.0%
6
Nature Communications
4913 papers in training set
Top 38%
4.0%
7
Journal of Experimental Medicine
106 papers in training set
Top 0.7%
4.0%
50% of probability mass above
8
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 27%
2.4%
9
Cell Reports Medicine
140 papers in training set
Top 2%
2.4%
10
Cell Metabolism
49 papers in training set
Top 0.8%
2.1%
11
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.7%
1.5%
12
Cancer Immunology Research
34 papers in training set
Top 0.3%
1.5%
13
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.3%
14
Nucleic Acids Research
1128 papers in training set
Top 13%
1.3%
15
Cell Stem Cell
57 papers in training set
Top 2%
1.2%
16
PLOS Biology
408 papers in training set
Top 14%
1.2%
17
Gastroenterology
40 papers in training set
Top 1%
0.9%
18
Leukemia
39 papers in training set
Top 0.7%
0.9%
19
Science
429 papers in training set
Top 18%
0.9%
20
iScience
1063 papers in training set
Top 26%
0.9%
21
Journal of Hepatology
18 papers in training set
Top 0.3%
0.9%
22
Nature
575 papers in training set
Top 15%
0.8%
23
Nature Cancer
35 papers in training set
Top 1%
0.8%
24
Science Advances
1098 papers in training set
Top 28%
0.8%
25
The Journal of Immunology
146 papers in training set
Top 2%
0.7%
26
Cell Chemical Biology
81 papers in training set
Top 4%
0.7%
27
Stem Cell Reports
118 papers in training set
Top 1.0%
0.7%
28
Aging Cell
144 papers in training set
Top 3%
0.7%
29
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
30
Cancer Cell
38 papers in training set
Top 2%
0.7%